Charles River Laboratories International, Inc. (NYSE:CRL) Director Sells $1,430,930.52 in Stock

Charles River Laboratories International, Inc. (NYSE:CRL) Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Charles River Laboratories International Trading Down 2.2 %

Shares of NYSE CRL traded down $4.75 during mid-day trading on Tuesday, hitting $215.94. The stock had a trading volume of 756,276 shares, compared to its average volume of 617,355. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.21 and a current ratio of 1.48. Charles River Laboratories International, Inc. has a 1 year low of $168.24 and a 1 year high of $275.00. The business has a 50 day moving average price of $194.37 and a two-hundred day moving average price of $208.00. The firm has a market cap of $11.04 billion, a P/E ratio of 27.62, a price-to-earnings-growth ratio of 5.80 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.72 EPS. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.2 EPS for the current fiscal year.

Charles River Laboratories International declared that its board has approved a share repurchase plan on Wednesday, August 7th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 9.6% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several research firms have weighed in on CRL. Barclays cut their price target on Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating for the company in a report on Thursday, August 8th. Redburn Atlantic began coverage on Charles River Laboratories International in a report on Monday, October 14th. They issued a “sell” rating and a $151.00 price target for the company. Citigroup cut Charles River Laboratories International from a “neutral” rating to a “sell” rating and cut their price target for the company from $215.00 to $175.00 in a report on Tuesday, October 1st. The Goldman Sachs Group lowered their target price on Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. Finally, JPMorgan Chase & Co. downgraded Charles River Laboratories International from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $270.00 to $205.00 in a report on Thursday, August 8th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, Charles River Laboratories International has a consensus rating of “Hold” and an average price target of $217.54.

Institutional Investors Weigh In On Charles River Laboratories International

A number of institutional investors have recently added to or reduced their stakes in the stock. Texas Permanent School Fund Corp grew its holdings in Charles River Laboratories International by 3.0% in the 1st quarter. Texas Permanent School Fund Corp now owns 10,602 shares of the medical research company’s stock valued at $2,873,000 after buying an additional 307 shares in the last quarter. Empowered Funds LLC grew its position in shares of Charles River Laboratories International by 10.0% in the first quarter. Empowered Funds LLC now owns 3,344 shares of the medical research company’s stock valued at $906,000 after purchasing an additional 304 shares during the period. Oppenheimer & Co. Inc. purchased a new stake in Charles River Laboratories International during the first quarter valued at about $473,000. Forsta AP Fonden lifted its stake in shares of Charles River Laboratories International by 17.0% in the first quarter. Forsta AP Fonden now owns 10,300 shares of the medical research company’s stock worth $2,791,000 after acquiring an additional 1,500 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new stake in Charles River Laboratories International during the first quarter valued at approximately $41,000. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).